Pneumonia is an infection in the lungs that causes inflammation in alveoli, making it difficult to breathe. Omadacycline is a new, aminomethylcycline antibiotic agent known to be active against pneumonia-causing agents. The objective of this study is to evaluate the efficacy of omadacycline in the treatment of community-acquired bacterial pneumonia.
This is a randomized, double-blind trial that included a total of 774 patients with community-acquired bacterial pneumonia. The participants were randomly assigned in a 1:1 ratio to receive omadacycline (100 mg intravenously) or moxifloxacin (400 mg intravenously), followed by an oral treatment in both groups after three days. The treatment duration was 7-14 days, and the primary outcome was an early clinical response to pneumonia.
Omadacycline was found non-inferior to moxifloxacin for early clinical response. The rates of investigator-assessed clinical response at post-treatment evaluation of the groups were 87.6% and 85.1%, respectively. Treatment-related adverse events were recorded in 41.1% of patients in the omadacycline group and 48.5% of the moxifloxacin group. The most frequent adverse events were gastrointestinal, mainly diarrhea. A total of 8 deaths in the omadacycline group and 4 in the moxifloxacin group occurred during the trial.
The research concluded that omadacycline was non-inferior to moxifloxacin for the treatment of community-acquired bacterial pneumonia.
Ref: https://www.nejm.org/doi/full/10.1056/NEJMoa1800201
